1263417-11-3

Basic information

• Product Name: (6S)-2-nitro-6-[(5-{[4-(trifluoromethoxy)phenyl]ethynyl}pyridin-2-yl)methoxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine
• Synonyms: (6S)-2-nitro-6-[(5-{[4-(trifluoromethoxy)phenyl]ethynyl}pyridin-2-yl)methoxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine
• CAS NO: 1263417-11-3
• Molecular Weight: 460.369
• Mol File: 1263417-11-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (6S)-2-nitro-6-[(5-{[4-(trifluoromethoxy)phenyl]ethynyl}pyridin-2-yl)methoxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine(CAS DataBase Reference)
• NIST Chemistry Reference: (6S)-2-nitro-6-[(5-{[4-(trifluoromethoxy)phenyl]ethynyl}pyridin-2-yl)methoxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine(1263417-11-3)
• EPA Substance Registry System: (6S)-2-nitro-6-[(5-{[4-(trifluoromethoxy)phenyl]ethynyl}pyridin-2-yl)methoxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine(1263417-11-3)

Safety Data

• Hazardous Substances Data: 1263417-11-3(Hazardous Substances Data)

Upstream product

• 187235-08-1 (S)‐2‐nitro‐6,7‐dihydro‐5H‐imidazo[2,1‐b][1,3]oxazin‐6‐ol 
• 1188329-32-9 (S)‐6‐((5‐bromopyridin‐2‐yl)methoxy)‐2‐nitro‐6,7‐dihydro‐5H‐imidazo[2,1‐b][1,3]oxazine 
• 168823-76-5 5-bromo-2-(chloromethyl)pyridine 
• 88139-91-7 (5-bromopyridin-2-yl)methanol 
• 1263417-32-8 (6S)-6-[(5-ethynylpyridin-2-yl)methoxy]-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine 
• 103962-05-6 1-iodo-4-(trifluoromethoxy)benzene 

Relevant articles and documents

Synthesis and Structure-Activity Relationships for Extended Side Chain Analogues of the Antitubercular Drug (6 S)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5 H -imidazo[2,1- b ][1,3]oxazine (PA-824)

Novel extended side chain nitroimidazooxazine analogues featuring diverse linker groups between two aryl rings were studied as a potential strategy to improve solubility and oral activity against chronic infection by Mycobacterium tuberculosis. Both lipop

NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY

The present invention relates to novel nitroimidazooxazines, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.